Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Longeveron Inc. - common stock (LGVN)
Company Research
Source: GlobeNewswire
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy womenLongeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company’s proprietary mesenchymal stem cells (MSCs) for the treatment of female patients with sexual dysfunction and improveme
Show less
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum [Yahoo! Finance]Yahoo! Finance
- Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) ForumGlobeNewswire
- Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with InflammagingGlobeNewswire
- Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)GlobeNewswire
- Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)GlobeNewswire
LGVN
Earnings
- 11/4/25 - Miss
LGVN
Sec Filings
- 11/12/25 - Form 8-K
- 11/4/25 - Form 8-K
- 11/4/25 - Form 10-Q
- LGVN's page on the SEC website